Flag of the European Union EU Clinical Trials Register Help

Clinical trials for lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,346 result(s) found for: lymphoma. Displaying page 45 of 68.
    «« First « Previous 41  42  43  44  45  46  47  48  49  Next» Last»»
    EudraCT Number: 2018-002179-17 Sponsor Protocol Number: M18-803 Start Date*: 2020-07-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Prospective, Open-Label, Single Arm, Phase 2, Multi-Center Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-cell Prolymphocytic Leukemia
    Medical condition: T-Cell Prolymphocytic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) FR (Completed) FI (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001727-11 Sponsor Protocol Number: 307940 / 106-20 Start Date*: 2006-03-17
    Sponsor Name:Schering AG, Global Medical Development
    Full Title: A phase III, open-label, prospective, two-armed, multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) ...
    Medical condition: Diffuse large B-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) IE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) HU (Prematurely Ended) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001691-39 Sponsor Protocol Number: UKM17_0023 Start Date*: 2019-07-16
    Sponsor Name:University Hospital Münster
    Full Title: LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
    Medical condition: Lymphoblastic lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) IE (Completed) NO (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002467-42 Sponsor Protocol Number: BO29562 Start Date*: 2016-05-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase Ib/II study evaluating the safety and efficacy of Atezolizumab in combination with obinutuzumab plus lenalidomide in patients with relapsed or refractory follicular lymphoma
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10016904 Follicle centre lymphoma, follicular grade I, II, III NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004034-42 Sponsor Protocol Number: GS-US-313-0125 Start Date*: 2013-10-31
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indole...
    Medical condition: Indolent Non-Hodgkin Lymphomas •Follicular lymphoma •Small lymphocytic lymphoma •Lymphoplasmacytic lymphoma (with or without Waldenström macroglobulinemia) •Marginal zone lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) SE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000074-19 Sponsor Protocol Number: GCP#03.01.020 Start Date*: 2014-10-24
    Sponsor Name:Gamida Cell Ltd
    Full Title: Full title of the trial: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematologic...
    Medical condition: High risk haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10025316 Lymphoma NOS LLT
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    17.0 100000004864 10009015 Chronic myeloid leukemia LLT
    17.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000275-42 Sponsor Protocol Number: IIL/DLCL04 Start Date*: 2006-01-20
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: A phase III, multicentric randomized study for the treatment of young patients with unfavorable prognosis Diffuse Large Cell B Lymphoma IPI 2-3 . Dose-dense chemotherapy Rituximab +/- intens...
    Medical condition: Patients with Diffuse Large B Cell Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    10012826 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001265-16 Sponsor Protocol Number: COEB071X2103 Start Date*: 2013-09-30
    Sponsor Name:Novartis Farma S.p.A
    Full Title: An Open-Label, Single-arm, Phase Ib/II study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR inhibitor) in Patients with CD79-mutant or ABC subtype Diffuse Large B-Cell Lymphoma
    Medical condition: Diffuse Large B-cell Lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000736-21 Sponsor Protocol Number: HLX01-FL03 Start Date*: 2020-07-02
    Sponsor Name:Shanghai Henlius Biotech Inc.
    Full Title: A Phase 3 Multi-Centre, Randomised, Double-Blind, Parallel-Arm Study to Evaluate the Efficacy and Safety of HLX01 Versus Rituximab (Mabthera®) as First Line Treatment in Patients With Low Tumour Bu...
    Medical condition: Low tumour burden follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002227-42 Sponsor Protocol Number: UCL/17/0192 Start Date*: 2019-02-14
    Sponsor Name:University College London
    Full Title: Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study
    Medical condition: Advanced classical Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-004845-25 Sponsor Protocol Number: BO29561 Start Date*: 2016-08-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and ritu...
    Medical condition: Follicular Lymphoma (FL) or Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10016904 Follicle centre lymphoma, follicular grade I, II, III NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-006370-15 Sponsor Protocol Number: WM RV 0426 (2008_15/0837) Start Date*: 2009-01-23
    Sponsor Name:CHRU de Lille
    Full Title: A multicenter phase I/II dose excalation study of lenalidomide in relapse/refractory Waldenström macroglobulinemia
    Medical condition: Maladie de Waldenstöm rédicivante ou réfractaire
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047804 Waldenstrom's macroglobulinaemia recurrent LLT
    9.1 10047805 Waldenstrom's macroglobulinaemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003629-16 Sponsor Protocol Number: BEB Start Date*: 2015-03-10
    Sponsor Name:University Hospital/Inselspital Berne, Department for Medical Oncology
    Full Title: A randomized phase II trial comparing BeEAM with BEAM as conditioning regimen for autologous stem cell transplantation (ASCT) in lymphoma patients (BEB-trial).
    Medical condition: Chemosensitive diffuse large B-cell lymphomas (DLBCL), follicular lymphomas (FL), and mantle cell lymphomas (MCL) in first or second remission
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005040-27 Sponsor Protocol Number: MDX060-03E Start Date*: 2006-03-10
    Sponsor Name:Medarex, Inc.
    Full Title: An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Previously Treated in Protocol MDX060-03
    Medical condition: Relapsed or Refractory Hodgkin’s Disease
    Disease: Version SOC Term Classification Code Term Level
    5.0 10020266 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000627-42 Sponsor Protocol Number: BCX1777-Bi-04-106 Start Date*: 2006-05-23
    Sponsor Name:BioCryst Pharmaceuticals Inc.
    Full Title: A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydr...
    Medical condition: B-cell acute lymphoblastic leukemia (B-ALL), which under WHO Guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036523 hlgt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001909-14 Sponsor Protocol Number: APL-B-021-13 Start Date*: 2016-03-14
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.
    Medical condition: Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002453 Angioimmunoblastic T-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003255-38 Sponsor Protocol Number: MO40597 Start Date*: 2019-03-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF GAZYVA SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA
    Medical condition: Follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061170 Follicle centre lymphoma, follicular grade I, II, III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001181-10 Sponsor Protocol Number: P003077 Start Date*: 2023-04-13
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand...
    Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001229-18 Sponsor Protocol Number: FIL_GAUDEALIS Start Date*: 2019-06-13
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study.
    Medical condition: recurrent / refractory follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002017-18 Sponsor Protocol Number: HEMATOVAC Start Date*: 2020-06-29
    Sponsor Name:CHU DE POITIERS
    Full Title: Clinical trial assessing the immunogenicity of an anti-pneumococcal combined vaccination strategy in adult patients treated for an acute leukemia or a lymphoma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    21.1 100000004865 10039244 Routine vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 41  42  43  44  45  46  47  48  49  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 18:58:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA